Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis.

Adverse public health effects of air pollution on global population

Exposure to high levels of air pollution can cause various health outcomes.

June 25, 2024

SARS-CoV-2 infection in coronary vessels linked to cardiovascular complications

Researchers reported that the increased long-term risk of acute cardiovascular complications associated with COVID-19 is linked to SARS-CoV-2 infecting coronary vessels and inducing the formation

October 3, 2023

Innovative cancer treatment approach yields promising results in pediatric patients

Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor

April 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.